OBJECTIVE: To assess whether structural brain damage as detected by magnetization transfer imaging (MTI) in Alzheimer's disease (AD) and mild cognitive impairment (MCI) is located in the gray matter (GM) and/or the white matter (WM). METHODS: Fifty-five AD patients, 19 MCI patients and 43 subjects with normal cognitive function participated in this study. GM and WM segmentations were generated from dual fast spin-echo MR images. These masks were co-registrated to MT images for volumetric MTI-analysis of the GM and WM. RESULTS: AD patients had a lower GM volume than controls. Both MCI and AD patients had more structural brain damage in both GM and WM than subjects with normal cognition. Cerebral lesion load in both GM and WM was associated with the degree of cognitive impairment. CONCLUSION: Using MTI, structural brain changes that are related to cognitive impairment could be demonstrated in both GM and WM of patients with AD and MCI. These results suggest that cerebral changes are present in GM and WM even before patients are clinically demented.
OBJECTIVE: To assess whether structural brain damage as detected by magnetization transfer imaging (MTI) in Alzheimer's disease (AD) and mild cognitive impairment (MCI) is located in the gray matter (GM) and/or the white matter (WM). METHODS: Fifty-five ADpatients, 19 MCI patients and 43 subjects with normal cognitive function participated in this study. GM and WM segmentations were generated from dual fast spin-echo MR images. These masks were co-registrated to MT images for volumetric MTI-analysis of the GM and WM. RESULTS:ADpatients had a lower GM volume than controls. Both MCI and ADpatients had more structural brain damage in both GM and WM than subjects with normal cognition. Cerebral lesion load in both GM and WM was associated with the degree of cognitive impairment. CONCLUSION: Using MTI, structural brain changes that are related to cognitive impairment could be demonstrated in both GM and WM of patients with AD and MCI. These results suggest that cerebral changes are present in GM and WM even before patients are clinically demented.
Authors: Cornelia Laule; Irene M Vavasour; Shannon H Kolind; David K B Li; Tony L Traboulsee; G R Wayne Moore; Alex L MacKay Journal: Neurotherapeutics Date: 2007-07 Impact factor: 7.620
Authors: Ying Wu; Hongyan Du; Pippa Storey; Christopher Glielmi; Fiona Malone; Shawn Sidharthan; Ann Ragin; Paul S Tofts; Robert R Edelman Journal: J Magn Reson Imaging Date: 2011-10-11 Impact factor: 4.813
Authors: Caterina Rosano; Sigurdur Sigurdsson; Kristin Siggeirsdottir; Caroline L Phillips; Melissa Garcia; Palmi V Jonsson; Gudny Eiriksdottir; Anne B Newman; Tamara B Harris; Mark A van Buchem; Vilmundur Gudnason; Lenore J Launer Journal: Neurobiol Aging Date: 2008-09-07 Impact factor: 4.673
Authors: Caroline K Jurgens; Reineke Bos; Jasper Luyendijk; Marie-Noëlle W Witjes-Ané; Jeroen van der Grond; Huub A M Middelkoop; Raymund A C Roos Journal: J Neurol Date: 2009-10-13 Impact factor: 4.849
Authors: C Granziera; A Daducci; A Donati; G Bonnier; D Romascano; A Roche; M Bach Cuadra; D Schmitter; S Klöppel; R Meuli; A von Gunten; G Krueger Journal: Neuroimage Clin Date: 2015-06-20 Impact factor: 4.881
Authors: Michiel Sala; Albert de Roos; Gerard J Blauw; Huub A M Middelkoop; J Wouter Jukema; Simon P Mooijaart; Mark A van Buchem; Anton J M de Craen; Jeroen van der Grond Journal: BMC Neurol Date: 2015-08-07 Impact factor: 2.474